(9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide;hydrochloride | 49746-04-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻喃类
• 英文名称: (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide;hydrochloride
• CAS: 49746-04-5
• 化学式: C23H30ClN3O2S2
• 分子量: 480.1
• InChiKey: ALDJVABCVUVJGI-SRJUEMFDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.89
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  77.5
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Hydrogel-containing medical articles and methods of using and making the same
  申请人：Faure Marie-Pierre

  公开号：US20050214376A1

  公开（公告）日：2005-09-29

  Medical articles including a hydrophilic water-swellable hydrogel and methods of using and making the articles are provided. The hydrogel may include a crosslinked mixture of a biocompatible polymer and a protein, such as polyethylene glycol and a soy protein. The hydrogel may further include an agent, such as diazolidinyl urea and iodopropynyl butylcarbamate, dispersed within the hydrophilic water-swellable hydrogel.

  提供了包括亲水性水膨胀性水凝胶的医疗文章以及使用和制作这些文章的方法。水凝胶可能包括生物相容性聚合物和蛋白质的交联混合物，例如聚乙二醇和大豆蛋白。水凝胶还可能在亲水性水膨胀性水凝胶中分散了一种药剂，如二嗪基脲和碘丙炔丁基氨基甲酸酯。
• Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
  申请人：Johnson Bankole A.

  公开号：US20100076006A1

  公开（公告）日：2010-03-25

  The present invention provides for the use of combinations of drugs to treat addictive disorders.

  本发明提供了利用药物组合治疗成瘾性障碍的方法。
• Neuroprotective agents
  申请人：——

  公开号：US20040063612A1

  公开（公告）日：2004-04-01

  The present invention relates to methods of treating neurodegenerative diseases with the neuroprotective agents of Formulas I-IV and XII and the other compounds described herein. The neuroprotective agents inhibit nitric oxide synthase enzymes and in particular nitric oxide synthase III (NOS III) and can be used to treat Alzheimer's disease.

  本发明涉及使用公式I-IV和XII以及本文中描述的其他化合物的神经保护剂治疗神经退行性疾病的方法。这些神经保护剂抑制一氧化氮合酶酶和特别是一氧化氮合酶III（NOS III），可用于治疗阿尔茨海默病。
• (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
  申请人：——

  公开号：US20030045567A1

  公开（公告）日：2003-03-06

  The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

  本发明涉及(−)-1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷及其药学上可接受的盐，包含(−)-1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷或其药学上可接受的盐的组合物，以及用于治疗或预防通过抑制多巴胺再摄取缓解的疾病的方法。在某些实施例中，该疾病为注意力缺陷障碍、抑郁症、肥胖症、帕金森氏病、抽动障碍或成瘾性疾病。所述(−)-1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷或其药学上可接受的盐最好基本上不含其相应的(+)对映体。
• (-)-1-(3,4-DichlorophenyI)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
  申请人：Dov Pharmaceuticals, Inc.

  公开号：US20030181508A1

  公开（公告）日：2003-09-25

  The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

  本发明涉及(−)-1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷及其药学上可接受的盐，包含(−)-1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷或其药学上可接受的盐的组合物，以及用于治疗或预防通过抑制多巴胺再摄取缓解的疾病的方法。在一种实施例中，该疾病是注意力缺陷障碍、抑郁症、肥胖症、帕金森病、抽动障碍或成瘾性障碍。所述的(−)-1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷或其药学上可接受的盐最好基本上不含其相应的(+)对映体。